Late-Stage Breakthroughs: How 2026's Top Clinical Platforms Are Redefining Cancer Treatment
Acrivon Therapeutics Announces Late-Breaking Oral Presentation at Upcoming European Society of Gynecological Oncology (ESGO) Annual International Congress
Co-Founder of Acrivon Therapeutics Peter Blume-Jensen Buys 2.6% More Shares [Yahoo! Finance]
Acrivon Therapeutics (NASDAQ:ACRV) was downgraded by analysts at
Wall St
Acrivon Therapeutics (NASDAQ:ACRV) had its "overweight" rating reaffirmed by analysts at Piper Sandler.